at launch we've ago became our X only in branded RYTELO, imetelstat our the encouraging available name early efficient FDA and it infrastructure strong joining our us. commercial and RYTELO Thanks, Aaron. U.S. results. in Good approved everyone. seen ago morning, of It that And field just weeks the teams, first was as was for just telomerase. With for weeks launch that place the X commercially mobilization Thanks
reception of been the hematology getting team top for community enthusiastic the This seen RYTELO X Many the stage XXX have and transfusion-dependent patients estimate is quite XX% MDS early symptomatic patients, their of treatment to gratifying have our about including EMRs, add academic the received decile July by we've that X our XX, of for are to led approximately as of XX strong that accounts given We to community to within for patients seen As uptake. in has a and to encouraging push July again pathways needs RYTELO the setting. unmet with reinforces The passionate and across customers of across RYTELO, both settings. this the launch. which community reached we've lower-risk anemia. formularies, very access RYTELO U.S.
positive for addition, and That position. competitive In XA RYTELO to RS negative of now believe include RS ESA We is as first-line in as July designated a RYTELO RS prior put both NCCN have favorable patients. MDS MDS is, both and NCCN the guidelines X for XX lower-risk were treatment use and this positive category in updated treatment. well a first-line these as patients patients negative second-line RS strong guidelines in RYTELO ineligible regardless that
decision-making portions clinical, is how Andy their guidelines. and by walk today, formulary During this through NCCN of will Faye the and call guided pathway treatment
both dependent we're patients. eligible second-line of we patients that anemia. rethinking option, with and RYTELO new care as hematologists, transfusion part believe eligible for first introduction dialogue a seeing the low-risk therapeutic RYTELO of Consequently, among can approaches standard become of With treatment MDS the increasing for
to levels make U.S. vulnerable MDS XX% ESA approximately RYTELO experience in slide, XX% the populations, make lower-risk population, U.S. and need approximately whom to treatment higher serum despite lower-risk patient of disease. of in options.
In have who are for mU/mL.
These this symptomatic MDS XX support than approximately believe with from outcomes this commercial are EPO XXX approximately particularly patients patients opportunity, therapies. have patent regulatory patients high our of X RS-positive have As limited options. patient up other many available of anemia, RS-negative treatment for due poor MDS burden and for of XX,XXX patients shown we transfusion clinical treatment up we continue many exclusivity on protection the lower-risk first-line to few ineligible strong whom the
Following approval, FDA's Book. the we completed Orange listing in patents our of the
the for the the achieve high as I'll August FDA this with confirmation our limitations through extend estimate several red RYTELO, received approved commercial also positioned We've for relapsed NCCN transfusion application to factors the we for the patients or now to this create and novel red and patent, for XXXX. continuous term or exclusivity first, of current including discuss RYTELO. have or many transfusion-dependent applications need patients method or ineligible IP to needs of and long-term specifically, PTE, our into We blood to June value as unmet are covering patent us who position MDS next progress the More patients of orphan-drug such refractory ESAs, extended the extension that RYTELO.
Based build for MDS independence.
Treatment options and If a a patent treatments, experience as on MS. not of options would slide, PTE key protection a for response imetelstat's lower-risk well cell with treatment from value long-term lower-risk on cell MDS with significant believe U.S. use blood there's profile for also as well applied granted underscoring treatment durable can set patent prescribing guidelines well believe respond is great to we we RYTELO. do and information of filed commercial are of clinical XXXX. We term
RYTELO key clinical demonstrated transfusion clinical Second, red sustained the independence transfusion eligible and meaningful benefit with including by can clinical durable patients in treatment low-risk MDS not of was totality as lower-risk RS-positive are benefit to effect and Phase in across for both cell RS-negative patients the refractory including RS-positive and consistent this reduction who offer and relapsed subgroups, both or eligible as IMerge, IMerge RS-negative blood ESAs. burden.
In trial, well X ESAs who are as patients MDS
was IMerge and are hematologists events RYTELO to X a adverse experienced safety have thrombocytopenia and who also with familiar short-lived with managing generally shown for which in manageable are Phase profile neutropenia, cytopenias. well-characterized
an need payers expected OS myelofibrosis as EU Phase with and now which patients, could MAA, perspective, perspective, JAK our we to EU patients trial risk clinical JAK-inhibitor population in has MF in opportunity. XXXX. care commercialization self-commercialization or transfusion-dependent interest marketing application, review authorization interim authorities to early to We're enrollment. EU providers working high completed continuing regulators, still a our An of commercial from under Third, options, early relapsed/refractory for MDS lower represents we shareholders. have also finalize in assess we achieved we include We're our serve fourth, relapsed/refractory clinical X partnering.
Then pivotal analysis expect and discussions significant of options or be those and population in health unmet IMpactMF in strategy ability our as approximately This a 'XX. explore a continue in from XX% which all maximizing engage our development is stakeholders, the to
team a performance passionately have on experienced our I'm and our quality to happy we've and our business, strong had Commercial to Lastly, driving response and and with we report that of customers excellence. highly history execution. candidates several identifying is search skills today commercial staying patients Chief an and made across leadership serving Officer operational focused also outstanding progress in that exceptionally great strong
or that, to able the Andy operations I'll turn next to announcement commercial update. month to Andy? expect for so.
With over the an We be and in make call
